In this issue:
6-month mortality/disability after ECMO in Australia
Long-term oxygen therapy in COPD
Upper respiratory S. pneumoniae colonisation and SARS-COV-2 infection
Effect of PCV10 in Nepal 4 years after introduction
Lung targeted miR-29 mimic for pulmonary fibrosis
Immunomodulatory treatment in unclassifiable ILD
Impact of insulin resistance on lung function loss and treatment response in asthma
Patients’ experiences of hospital-based opt-out tobacco dependency treatment
Predicting future influenza burden after relaxation of COVID-19 measures
First-line furmonertinib vs. gefitinib for EGFR mutated non-small-cell lung cancer
Please login below to download this issue (PDF)